|Day Low/High||28.04 / 37.50|
|52 Wk Low/High||5.00 / 51.90|
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: FUNC, HAIN, PRCP, SHEN, SSNT Downgrades: AVAV, CLDT, PAG, TLF, TOWR Initiations: OPNT, TLND Read on to get TheStreet Quant Ratings' detailed report:
Company Received Additional Payment From SWK Funding LLC Based on Achievement of $25 Million Net Sales of NARCAN® Nasal Spray Milestone
Listing Strengthens IP Position and Enhances NARCAN Product Exclusivity
Overdoses kill 91 people a day.
Listing Bolsters IP Estate and Enhances NARCAN Product Exclusivity
Topline Data Expected in the First Half of 2018
Listings Significantly Strengthen IP Estate and Enhance NARCAN Product Exclusivity
Company Plans Additional Clinical Trials This Year; Topline Data Expected in 2018
Company to pursue up-listing to a major stock exchange in 2017
2mg Formulation Indicated for Patients At-Risk for Severe Opioid Withdrawal
SWK to Acquire Certain NARCAN® Royalties For Up to $17.5 Million
Thomas Brings Global Pharmaceutical and Financial Expertise to Opiant's Board
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.